Table 1.
Patient characteristics in model development and validation cohort
| Characteristic | Mayo validation cohort (N=276) | Published model development cohort* (N=350) |
|---|---|---|
| Age (years), median (range) | 64 (21–91) | 61 (34–86) |
| Primary site of disease, N (%) | ||
| Ovary | 186 (67.4) | 264 (75.4) |
| Peritoneal | 72 (26.1) | 44 (12.6) |
| Fallopian tube | 18 (6.5) | 42 (12.0) |
| FIGO stage, N (%) | ||
| IIIA/B | 0 | 8 (2.3) |
| IIIC | 210 (76.1) | 248 (70.9) |
| IV | 66 (23.9) | 94 (26.9) |
| FIGO grade, N (%) | ||
| 1 or 2 | 13 (4.7) | 19 (5.4) |
| 3 | 259 (93.8) | 328 (93.7) |
| Unknown | 4 (1.4) | 3 (0.9) |
| Histology, N (%) | ||
| Endometrioid/clear cell | 17 (6.1) | 2 (0.6) |
| Serous | 236 (85.5) | 314 (89.7) |
| Mixed/Other | 23 ( (8.3) | 34 (9.7) |
| Preoperative CA-125 (U/mL), median (range) | 729 (10–45400) | 860 (9–38100) |
| ASA score, N (%) | ||
| 1 | 3 (1.1) | 10 (2.9) |
| 2 | 139 (50.4) | 158 (45.1) |
| 3 | 133 (48.2) | 179 (51.1) |
| 4 | 1 (0.4) | 3 (0.9) |
| Residual disease (RD), N (%) | ||
| RD0, no visible disease | 136 (49.3) | 117 (33.4) |
| RD1, 0.1–1.0 cm | 114 (41.3) | 144 (41.1) |
| RD >1 cm | 26 (9.4) | 89 (25.4) |
Abbreviations: ASA, American Society of Anesthesiologists; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range; SD, standard deviation.
*
Data from Suidan 2014 publication